Sign Out
Known hypersensitivity to ezetimibe or any ingredient in the formulation.
Ezetimibe, in combination with a HMG-CoA reductase inhibitor (statin), is contraindicated in patients with active liver disease or unexplained, persistent increases in serum aminotransferase (transaminase) concentrations.
Concomitant use of the fixed combination of ezetimibe and simvastatin with potent inhibitors of cytochrome P-450 (CYP) isoenzyme 3A4, cyclosporine, danazol, or gemfibrozil is contraindicated.
Continue with Google